Sigyn Therapeutics corrects typo in prior 8-K; confirms 320K share and warrant sale for $400K

Sigyn Therapeutics, Inc.

Amendment corrects share count to 320,000 shares of common stock and warrants for 320,000 shares.
Gross proceeds from sale to accredited investors total $400,000, consummated October 20, 2021.
Warrants allow purchase of 320,000 shares of common stock; terms not specified in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.